WHO ICTRP trial
A Phase 3, Double-blind, Placebo-controlled and Open-label Efficacy and…
NL-OMON52137 · Overview of Medical Research in the Netherlands (NL-OMON) · Not Recruiting
Key facts
| Trial ID | NL-OMON52137 |
|---|---|
| Public title | A Phase 3, Double-blind, Placebo-controlled and Open-label Efficacy and Long-term Safety Study of Firibastat (QGC001) Administered Orally, Once Daily, for Up to 48 Weeks in Patients with Difficult-to-treat/Resistant Hypertension |
| Scientific title | A Phase 3, Double-blind, Placebo-controlled and Open-label Efficacy and Long-term Safety Study of Firibastat (QGC001) Administered Orally, Once Daily, for Up to 48 Weeks in Patients with Difficult-to-treat/Resistant Hypertension - REFRESH |
| Primary sponsor | Quantum Genomics |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 3 |
| Countries | Belgium;Bulgaria;Canada;Czechia;France;Germany;Hungary;Italy;Korea (the Republic of);Netherlands;Poland;Russian Federation ;Slovakia;Spain;Taiwan (Province of China);United States of America |
| Conditions | Difficult to treat and Treatment-resistant high blood pressure;10082206;Difficult to treat and Treatment-resistant high blood pressure |
| Interventions | This trial will evaluate the firibastat (QGC001) for the treatment of Hypertension. The trial will be divided into Period 1, 2 and 3. The trial will have 2 groups of patients. Patients will be randomly assigned to Group A (who will receive… |
| Registration date | Jun 8, 2022 |
| Target size | 35 |
| Secondary IDs | 2021-001404-14;NCT04857840;NL78941.100.21 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: